Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2–expressing salivary gland carcinoma: a pooled analysis of two phase I studies

By S. Takahashi, H. Bando, Ichiro Kinoshita, S. Modi, J. Tsurutani, Y. Bang, Yuta Sato, Shunsuke Nakatani, Caleb Lee, M. Sugihara and 2 more. 2024

Subfields: Oncology, Otorhinolaryngology, Pharmacology

Citations in the corpus

• Trastuzumab-deruxtecan shows interesting disease control in a multitreated patient with ERBB2 amplified parotid carcinoma, a case report (2025, unknown): “19 However, more real-life data are required to build a clinical trial in the hope of obtaining a major response, as has been observed with this molecule in other types of cancer.”